Johnson & Johnson (JNJ) Target Of FDA Wrath
McNeil-PPC, a Johnson & Johnson (NYSE: JNJ) division, has kicked off a broad based recall of approximately 500 lots of drugs like Tylenol, Motrin, and Benadryl.
The recall, announced on Friday, drew the wrath of the FDA on Johnson & Johnson for not acting fast enough on complaints of a moldy, mildew-like odor on their drugs.
The problem first surfaced in early 2008, but the company identified it as an ‘issue’ only in September 2008. The FDA has issued a warning letter to McNeil stating that failure to rectify the problem could result in legal action and seizure.
The company received a number of complaints of stomach problems, which it has traced to a chemical applied on wooden pallets used in the transport of drugs. McNeil started recalling lots in November 2009.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.